Literature DB >> 6307604

Plasmid-independent resistance of 'gray' colony variants of a strain of Serratia marcescens resistant to amikacin, cefotaxime and lamoxactam.

W H Traub, M Spohr, D Bauer.   

Abstract

A multiple-drug-resistant strain of Serratia marcescens (serotype O14:H12; bacteriocin type 18), which was recovered repeatedly from the respiratory tract of an intensive care unit patient, yielded 'gray' colony phenotypic variants which were greater than or equal to four-fold less susceptible to amikacin, cefotaxime, and lamoxactam, but not to netilmicin and N-formimidoyl thienamycin, as compared with 'opaque' (wild-type) colony variants. The 'gray' variants proved phenotypically highly unstable and displayed comparable low virulence for NMRI mice (intraperitoneal route). The 'opaque' and 'gray' variants of this strain carried a nonconjugative, 46-megadalton resistance (R) plasmid, as determined by DNA agarose gel electrophoresis. The R-plasmid-mediated resistance against chloramphenicol, gentamicin, kanamycin, mezlocillin, piperacillin, triple sulfonamides, and cotrimoxazole, as demonstrated with 'curing' experiments. The mechanism of the novel amikacin-beta-lactam antibiotic resistance phenomenon remained undetermined.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6307604     DOI: 10.1159/000238208

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  3 in total

1.  Spontaneous quinolone resistance in Serratia marcescens due to a mutation in gyrA.

Authors:  B L Masecar; N J Robillard
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

2.  Outer membrane and porin characteristics of Serratia marcescens grown in vitro and in rat intraperitoneal diffusion chambers.

Authors:  F Malouin; G D Campbell; M Halpenny; G W Becker; T R Parr
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

3.  Aminoglycoside resistance patterns of Serratia marcescens strains of clinical origin.

Authors:  R Coria-Jiménez; C Ortiz-Torres
Journal:  Epidemiol Infect       Date:  1994-02       Impact factor: 2.451

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.